Role of myocardial 123I-mIBG innervation imaging in the diagnosis of neurodegenerative diseases
- 22 Downloads
Neurodegenerative diseases occur when neurons in the central and/or peripheral nervous systems lose function over time and ultimately die. They are characterized by common cellular and molecular mechanisms including protein aggregation and inclusion body formation, categorising each type of disease. Therefore, the definitive diagnosis is at post-mortem, based on pathology. However, the development of various molecular imaging techniques has enabled pathological changes to be inferred in vivo. Decreased myocardial 123I-mIBG uptake has been reported in some patients with neurodegenerative diseases. This review is aimed to synthesise the basis, methodology and clinical role of myocardial 123I-mIBG imaging in the diagnosis of certain neurodegenerative diseases, focusing on its utility to differentiate some neurodegenerative Parkinsonisms between them, and to differentiate dementia with Lewy bodies from Alzheimer’s disease and other dementias.
Keywords123I-mIBG Myocardial innervation Neurodegenerative diseases Parkinsonisms Alzheimer's disease Differential diagnosis
Compliance with ethical standards
Conflict of interest
The author has no conflict of interest.
This article is a review article and does not contain any studies with human or animal subjects performed by any of the authors.
- 2.Parkinson’s Foundation. http://www.parkinson.org/Understanding-Parkinsons/What-is-Parkinsons/Types-of-Parkinsonisms. Accessed 1 Jul 2018
- 3.World Health Organization. http://www.who.int/news-room/facts-in-pictures/detail/dementia. Accessed 1 Jul 2018
- 4.Alzheimer’s Association. https://www.alz.org/alzheimers-dementia/what-is-dementia. Accessed 1 Jul 2018
- 10.Flotats A, Carrió I, Agostini D, Le Guludec D, Marcassa C, Schäfers M, EANM Cardiovascular Committee, European Council of Nuclear Cardiology et al (2010) Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging 37:1802–1812CrossRefPubMedGoogle Scholar
- 34.Treglia G, Stefanelli A, Cason E, Cocciolillo F, Di Giuda D, Giordano A (2011) Diagnostic performance of iodine-123-metaiodobenzylguanidine scintigraphy in differential diagnosis between Parkinson’s disease and multiple-system atrophy: a systematic review and a meta-analysis. Clin Neurol Neurosurg 113:823–829CrossRefPubMedGoogle Scholar
- 52.Sonni I, Ratib O, Boccardi M, Picco A, Herholz K, Nobili F, Geneva Task Force for the Roadmap of Alzheimer’s Biomarkers et al (2017) Clinical validity of presynaptic dopaminergic imaging with 123I-ioflupane and noradrenergic imaging with 123I-MIBG in the differential diagnosis between Alzheimer’s disease and dementia with Lewy bodies in the context of a structured 5-phase development framework. Neurobiol Aging 52:228–242CrossRefPubMedGoogle Scholar